Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
Onco-Innovations Limited (ONNVF) pioneers next-generation cancer therapies through AI-driven drug discovery and nanoparticle delivery systems. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s oncology research advancements and strategic developments.
Access real-time announcements including clinical trial milestones, technology licensing agreements, and partnership updates with academic institutions. Our curated feed ensures you stay informed about key initiatives like SynoGraph AI platform enhancements and nanoparticle formulation breakthroughs without promotional bias.
Discover updates across critical categories: preclinical study results, intellectual property filings, OTCQB market disclosures, and collaborative research projects. Each update is vetted for relevance to the company’s mission of advancing precision oncology through cutting-edge science.
Bookmark this page for streamlined tracking of Onco-Innovations’ progress in developing therapies that target solid tumors while minimizing treatment toxicity. Verify time-sensitive information directly through official filings and press releases as you conduct due diligence.
Onco-Innovations (CBOE CA:ONCO) has appointed Dr. John Mackey, Professor Emeritus in Oncology at the University of Alberta, to its Scientific and Clinical Advisory Board. Dr. Mackey brings extensive experience in oncology, clinical trials, and drug development, having previously served as Director of the Clinical Trial Unit at Cross Cancer Institute and Executive Director of TRIO.
Dr. Mackey's credentials include co-founding Pacylex Pharmaceuticals, serving as CEO of illumiSonics, holding 12 patents, and co-authoring over 300 peer-reviewed publications. His expertise will support Onco's PNKP inhibitor program development, particularly in clinical strategy and trial methodology.
Onco-Innovations (OTCQB:ONNVF) has announced that over 90% of its $0.60 common share purchase warrants have been successfully exercised over an eight-month period. This high conversion rate has resulted in additional capital inflow for the company through non-dilutive financing.
CEO Thomas O'Shaughnessy highlighted that the significant warrant exercise rate demonstrates strong shareholder confidence in the company's strategic direction and validates their ability to generate internal capital.
Onco-Innovations (OTCQB:ONNVF) has successfully closed its previously announced non-brokered private placement, raising $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit comprises one common share and one warrant, with warrants exercisable at $2.05 per share until August 13, 2028.
The company will utilize the proceeds for general corporate and working capital purposes, including operational and R&D objectives. Additionally, 2,439 administrative shares were issued to a third party for services related to the placement. All securities are subject to a four-month hold period ending December 14, 2025.
Onco-Innovations (OTCQB:ONNVF) has signed a Start-Up Agreement with Avance Clinical to prepare for its first-in-human trial of their novel PNKP inhibitor therapy. The agreement focuses on developing crucial regulatory and clinical documentation required for human testing approvals.
Under the partnership, Avance will provide comprehensive support including: development of an Investigator's Brochure, creation of clinical trial protocols, conducting nonclinical gap analysis, and preparation for a pre-IND meeting with the FDA. The therapy targets advanced-stage cancers with PTEN1 or SHP-12 deficiency.
Onco-Innovations Limited (OTCQB:ONNVF) announced that its subsidiary Inka Health has been selected by OneMedNet (Nasdaq:ONMD) to lead an AI-driven oncology data analytics initiative. The project aims to develop external control arms (ECAs) using OneMedNet's regulatory-grade patient data to accelerate cancer therapy development.
The collaboration will utilize Inka Health's SynoGraph platform to validate an ECA for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer. This initiative targets the Real-World Evidence (RWE) market, projected to reach $4.6 billion by 2030. The project aims to demonstrate how real-world data can replicate traditional clinical trial results more efficiently, potentially reducing development costs and timelines.
The companies plan to submit their findings to ISPOR Europe 2025, positioning themselves at the forefront of AI-driven oncology research and drug development.
Onco-Innovations (OTCQB:ONNVF) has announced a non-brokered private placement to raise up to $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit includes one common share and one warrant, with warrants exercisable at $2.05 for 36 months.
The company will issue additional shares as a 1% administrative fee to a third party. Additionally, Onco-Innovations has approved the grant of 119,785 stock options and 960,000 restricted share units (RSUs) under its equity incentive plan. The proceeds will support general corporate purposes and R&D objectives.
Onco-Innovations (CBOE CA:ONCO) has appointed renowned chemist Dr. Dennis Hall to its Scientific and Clinical Advisory Board. Dr. Hall, a Professor of Chemistry at the University of Alberta and Tier 1 Canada Research Chair in Boron Chemistry, brings extensive expertise in organoboron chemistry, catalysis, and medicinal chemistry.
Dr. Hall's impressive credentials include over 175 peer-reviewed publications, 18,000+ citations, and numerous prestigious awards. He will provide strategic guidance on the company's R&D initiatives, particularly focusing on the development of PNKP Inhibitor Technology NP/A83 for oncology applications.
Onco-Innovations (OTCQB:ONNVF) has entered into a services agreement with Redwood AI to advance the development of its exclusively-licensed Polynucleotide Kinase Phosphatase (PNKP) Compound technology. The collaboration aims to enhance the company's drug development capabilities through AI-driven chemistry tools.
The partnership will leverage Redwood AI's expertise in synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the PNKP technology. The proprietary compound targets solid tumors by increasing sensitivity to radiation and DNA-damaging chemotherapies. This strategic collaboration is designed to support Onco's progression toward First-in-Human studies by improving scalability, safety, and discovery precision.
Onco-Innovations (CBOE CA:ONCO) has appointed Dr. Islam Mohamed as Chair of its Scientific and Clinical Advisory Board. Dr. Mohamed brings over 20 years of experience as a Radiation Oncologist, clinical researcher, and biotechnology advisor.
Dr. Mohamed's expertise spans lung, breast, skin cancers, and sarcoma treatment at BC Cancer, with significant experience in stereotactic radiation delivery. He has led numerous clinical trials and served on research ethics boards and national committees. His role will involve providing strategic guidance on R&D initiatives and facilitating clinical and scientific collaboration.
Onco-Innovations (OTCQB:ONNVF) has signed a crucial agreement with Nucro-Technics to conduct IND-enabling preclinical studies for its lead drug candidate. The studies will focus on the company's PNKP inhibitor (NP/A83), which targets advanced-stage, PTEN- or SHP-1-deficient cancers.
The comprehensive testing program includes drug metabolism testing (ADME studies) and GLP-compliant safety studies required for regulatory approval. Nucro-Technics, a Toronto-based CRO with 55 years of experience, will evaluate the drug's bioavailability, biodistribution, pharmacokinetics, and safety profile to support future IND applications with both FDA and Health Canada.
The agreement represents a significant milestone toward initiating Phase I/II clinical trials, including validation of analytical methods and safety assessment of the novel polymer delivery system (mPEO-bPBCL).
FAQ
What is the current stock price of Onco-Innovations (ONNVF)?
